Are you looking to kickstart your journey to a healthier you? Look no further than Skinny Shot Wellness! This innovative online platform offers a range of services to help you transform your health and achieve your weight loss goals.
Compounded Semaglutide and Tirzepatide, when combined with sustainable lifestyle changes such as improved diet and daily physical activity, have been proven to lead to significant weight loss and health improvement. Start your journey with us today.
At Skinny Shot Wellness, you can access weight loss medications, compounded semaglutide, and compounded tirzepatide, from the comfort of your own home. We understand the barriers that exist to you reaching your wellness goals and seek to bridge the gap and make your goals a reality. The website features a user-friendly interface, making it easy to purchase medications, schedule free consultations, and complete intake and consent forms online.
Tirzepatide has been proven in studies to be more effective at weight loss with 21.1% weight loss compared to 10-14% in Semaglutide. Additionally, patients report less side effects with Tirzepatide and studies showed less risk of hypoglycemia. If you need help decided which medication is best for you, book your consult first and discuss this further with your provider. Online consent and intake form must be completed prior to your consultation.
Whether you're just starting your health and wellness journey or looking to take your progress to the next level, Skinny Shot Wellness has everything you need to succeed. Visit the website today to learn more about how you can transform your health and achieve your weight loss goals with Skinny Shot Wellness.
REFERENCES
De Block, Christophe, et al. “Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.” Diabetes, Obesity and Metabolism, vol. 25, no. 1, 31 Aug. 2022, pp. 3–17, https://doi.org/10.1111/dom.14831.
Azuri, Joseph, et al. “Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.” Diabetes, Obesity and Metabolism, vol. 25, no. 4, 27 Dec. 2022, pp. 961–964, https://doi.org/10.1111/dom.14940.
Komentarze